Aoife Brennan/LinkedIn
Jun 12, 2026, 14:27
Aoife Brennan: Ongoing Budo Study Demonstrates Potential in Challenging ITP Population
Aoife Brennan, Board Member at Critical Path Institute (C-Path), President and CEO of Climb Bio, shared a post on LinkedIn:
“Delighted to share data from our ongoing study of budo in ITP today at EHA.
Many of the patients enrolled had a higher number of prior lines of therapy than baseline platelet count which illustrates the need for new treatments that provide durable treatment response.
Immense gratitude to the patients and investigators who are participating and congratulations to the team Climb Bio.”
Stay updated with Hemostasis Today.
-
Oct 25, 2026, 05:30Denis Oduor: Whole Blood and Component Therapy in Clinical Practice
-
Oct 25, 2026, 02:18Dai H. Chung: Delivering Lyfgenia to Pediatric Patients With Sickle Cell Disease
-
Oct 25, 2026, 02:17Marilyn Baffoe-Bonnie: What Does It Mean to Be Cured of Sickle Cell Disease?
-
Oct 25, 2026, 02:15Tamara Stipcevic: A Hand-Powered Device for Rapid Blood Typing and Hematocrit Estimation
-
Oct 25, 2026, 02:14Rhonda Patrick: Microplastics Generate Damaging Free Radicals Simply by Contacting Water
-
Oct 25, 2026, 02:12Chokri Ben Lamine: Rilzabrutinib – Oral BTK Inhibitor for ITP
-
Oct 25, 2026, 02:12Michael H. Tomasson: Self-Experimentation That Revealed the Immune Mechanism of ITP
-
Oct 25, 2026, 02:10Nabiha Huq Saifee: Do You Help Make Platelet Transfusion Decisions Before Lumbar Puncture?
-
Oct 25, 2026, 02:09Sebastian Szmit: Congratulations to Isabelle Mahé on Her New Cardio-Oncology Paper